A Trial of INS068 in Patients With Type 2 Diabetes Not Adequately Controlled With One or Two Oral Antidiabetics

PHASE2CompletedINTERVENTIONAL
Enrollment

179

Participants

Timeline

Start Date

February 4, 2021

Primary Completion Date

May 28, 2022

Study Completion Date

May 28, 2022

Conditions
Type 2 Diabetes
Interventions
DRUG

INS068 injection

INS068 injected subcutaneously once daily. Treat-to-target dose titration during the trial

DRUG

Insulin Degludec

Insulin Degludec injected subcutaneously once daily. Treat-to-target dose titration during the trial

Trial Locations (35)

3050

The Royal Melbourne Hospital, Melbourne

3081

Austin Health (Heidelberg Repatriation Hospital), Melbourne

4064

Core Research Group Pty Ltd, Brisbane

32127

Progressive Medical Research, Port Orange

33016

New Generation of Medical Research, Hialeah

33024

ALL Medical Research, LLC, Cooper City

43201

Endocrinology Associates, Inc, Columbus

45005

Prestige Clinical Research, Franklin

50265

Iowa Diabetes and Endocrinology Research Center, West Des Moines

77040

Juno Research, LL, Houston

77054

Juno Research, LLC - Medical Center Office, Houston

77074

Juno Research, LLC - Southwest Houston Site, Houston

78229

Endeavor Clinical Trials, San Antonio

90057

National Research Institute - Wilshire, Los Angeles

90255

National Research Institute - Huntington Park, Huntington Park

90717

Torrance Clinical Research Institute Inc, Lomita

95648

Clinical Trials Research, Lincoln

100044

Peking University People's Hospital, Beijing

110004

Shengjing Hospital Of China Medical University, Shenyang

200031

Shanghai Xuhui District Central Hospital, Shanghai

200062

Shanghai Putuo District Central Hospital, Shanghai

210008

Nanjing Drum Tower Hospital,The Affiliated Hospital of Nanjing University Medical School, Nanjing

210009

Zhongda Hospital Affiliated to Southeast University, Nanjing

330006

Jiangxi Provincial People's Hospital, Nanchang

400010

The Second Affiliated Hospital of Chongqing Medical University, Chongqing

404100

Chongqing University Three Gorges Hospital, Chongqing

430030

Tongji Hospital of Tongji Medical College, Huazhong University of Scince and Technology, Wuhan

450000

The First Affiliated Hospital of Zhengzhou University, Zhengzhou

570311

Hainan General Hospital, Haikou

610000

West China Hospital,Sichuan University, Chengdu

644000

Yibin Second People's Hospital, Yibin

710004

The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an

33014-3616

Clinical Pharmacology of Miami, LLC, Miami

050000

The Second Hospital of Hebei Medical University, Shijiazhuang

030001

First Hospital of Shanxi Medical University, Taiyuan

All Listed Sponsors
lead

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY

NCT04663282 - A Trial of INS068 in Patients With Type 2 Diabetes Not Adequately Controlled With One or Two Oral Antidiabetics | Biotech Hunter | Biotech Hunter